Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1997 1
2001 1
2003 1
2006 1
2007 2
2008 3
2009 3
2011 2
2012 1
2013 4
2014 3
2015 2
2016 3
2017 2
2018 3
2019 6
2020 6
2021 11
2022 4
2023 4
2024 11
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Bardia A, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamilton E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortes J, Tsai M, Vahdat L, Diéras V, Carey LA, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Hurvitz SA. Bardia A, et al. Among authors: recalde s. Ann Oncol. 2021 Sep;32(9):1148-1156. doi: 10.1016/j.annonc.2021.06.002. Epub 2021 Jun 8. Ann Oncol. 2021. PMID: 34116144 Free article. Clinical Trial.
Breast Cancer Patient's Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II-III Disease.
Falo C, Azcarate J, Fernandez-Gonzalez S, Perez X, Petit A, Perez H, Vethencourt A, Vazquez S, Laplana M, Ales M, Stradella A, Fullana B, Pla MJ, Gumà A, Ortega R, Varela M, Pérez D, Ponton JL, Cobo S, Benitez A, Campos M, Fernández A, Villanueva R, Obadia V, Recalde S, Soler-Monsó T, Lopez-Ojeda A, Martinez E, Ponce J, Pernas S, Gil-Gil M, Garcia-Tejedor A. Falo C, et al. Among authors: recalde s. Cancers (Basel). 2024 Jun 30;16(13):2421. doi: 10.3390/cancers16132421. Cancers (Basel). 2024. PMID: 39001483 Free PMC article.
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial.
Gion M, Blancas I, Cortez-Castedo P, Cortés-Salgado A, Marmé F, Blanch S, Morales S, Díaz N, Calvo-Plaza I, Recalde S, Martínez-Bueno A, Ruiz-Borrego M, Llabrés E, Taberner MT, de Laurentiis M, García-Vicente S, Guerrero JA, Boix O, Rodríguez-Morató J, Sampayo-Cordero M, Antonarelli G, Pérez-García JM, Cortés J, Llombart-Cussac A; ATRACTIB Trial Investigators. Gion M, et al. Among authors: recalde s. Nat Med. 2025 Aug;31(8):2746-2754. doi: 10.1038/s41591-025-03734-3. Epub 2025 Jun 4. Nat Med. 2025. PMID: 40467896 Free PMC article. Clinical Trial.
[Genetics and ARMD: from the laboratory to the consulting room].
García Layana A, Zarranz-Ventura J, Fernández Robredo P, Recalde S, Rodríguez de Córdoba S; Grupo Español de Investigación Cooperativa en DMAE. García Layana A, et al. Among authors: recalde s. Arch Soc Esp Oftalmol. 2011 Apr;86(4):101-2. doi: 10.1016/j.oftal.2011.03.005. Arch Soc Esp Oftalmol. 2011. PMID: 21569917 Spanish. No abstract available.
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial.
Pérez-García JM, Gion M, Ruiz-Borrego M, Blancas I, López-Miranda E, Blanch S, Recalde S, Rendo CR, González X, Ancizar N, Morales S, Cortez P, Piwowarska Z, Shimizu E, Guerrero JA, Sampayo-Cordero M, Martínez-Bueno A, Cortés J, Llombart-Cussac A. Pérez-García JM, et al. Among authors: recalde s. EClinicalMedicine. 2025 Jun 18;85:103309. doi: 10.1016/j.eclinm.2025.103309. eCollection 2025 Jul. EClinicalMedicine. 2025. PMID: 40606525 Free PMC article.
Matrix Metalloproteinase 10 Contributes to Choroidal Neovascularisation.
González-Zamora J, Hernandez M, Recalde S, Bezunartea J, Montoliu A, Bilbao-Malavé V, Orbe J, Rodríguez JA, Llorente-González S, Fernández-Robredo P, García-Layana A. González-Zamora J, et al. Among authors: recalde s. Biomedicines. 2022 Jun 30;10(7):1557. doi: 10.3390/biomedicines10071557. Biomedicines. 2022. PMID: 35884862 Free PMC article.
Could Children's Myopization Have Been Avoided during the Pandemic Confinement? The Conjunctival Ultraviolet Autofluorescence (CUVAF) Biomarker as an Answer.
de la Puente M, Irigoyen-Bañegil C, Ortega Claici A, González-Zamora J, Bilbao-Malavé V, Fernandez-Robredo P, Hernández M, Barrio J, García-Layana A, Recalde S. de la Puente M, et al. Among authors: recalde s. Biomedicines. 2024 Feb 1;12(2):347. doi: 10.3390/biomedicines12020347. Biomedicines. 2024. PMID: 38397949 Free PMC article.
Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Age Related Macular Degeneration, Role in Pathophysiology, and Possible New Therapeutic Strategies.
Bilbao-Malavé V, González-Zamora J, de la Puente M, Recalde S, Fernandez-Robredo P, Hernandez M, Layana AG, Saenz de Viteri M. Bilbao-Malavé V, et al. Among authors: recalde s. Antioxidants (Basel). 2021 Jul 23;10(8):1170. doi: 10.3390/antiox10081170. Antioxidants (Basel). 2021. PMID: 34439418 Free PMC article. Review.
73 results